ProHealth health Vitamin and Natural Supplement Store and Health
Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help

|
|
|
|

Trending News

Missing protein explains link between obesity, diabetes

Fish oil use associated with brain volume preservation

The Brain Boosting and Fatigue Fighting B-12

Genetic basis for distinct type of autism uncovered

Unsuspected aspect of immune regulation revealed: Role of B cells

IBS, Crohn’s Disease, Colitis, and Other Digestive Disorders

Explaining 'Healthy' Obesity

Sinus Congestion and Sinusitis, Healing Naturally

Ginger's Many Evidence-Based Health Benefits Revealed

Omega 3 Fatty Acids Lessen Severity of Osteoarthritis in Mice

 
Print Page
Email Article

Kansas Clinic's Patented Test Measures Energy Metabolism in Chronic Fatigue Syndrome

  [ 7 votes ]   [ 1 Comment ]
www.ProHealth.com • April 11, 2012


 Article:
The Assessment of the Energy Metabolism in Patients with Chronic Fatigue Syndrome by Serum Fluorescence Emission
- Source: Alternative Therapies in Health and Medicine, Jan-Feb 2012

By Nina Mikirova, Joseph Casciari, Ronald Hunninghake

[Note: The fatigue marker discussed here is NAD(P)H, the reduced form of the coenzyme NADP. It can be measured via the level of its fluorescence when blood serum is irradiated. In a previous study these researchers found that lower concentrations of NAD(P)H were indicative of reduced energy metabolism in cancer patients. The full text PDF of this article is available free at www.riordanclinic.org/research/articles/AT-2012-v18.pdf.]

Context: Chronic fatigue syndrome (CFS) is a debilitating fatigue illness that has unknown etiology and lacks an objective diagnostic marker.

Objective: To examine the metabolic component of CFS to determine if practitioners can use serum NAD(P)H concentration measurements to monitor metabolism and fatigue status in patients with CFS.

Design: The research team conducted a case-control study, comparing a group of patients who were diagnosed with CFS with a control group of healthy subjects. The team obtained venous blood samples from fasting patients to examine the serum NAD(P)H concentrations.

Setting: The study occurred at the Riordan Clinic in Witchita, Kansas.

Participants: The study included 44 CFS patients at the Riordan Clinic and 30 healthy control participants.

The CFS patients presented a spectrum of symptoms that had existed for at least 6 months: new, unexplained, persistent, or relapsing chronic fatigue that bed rest did not resolve and that was severe enough to reduce daily activity significantly - by 50% - in conjunction with headache, muscle pain, pain in multiple joints, and unrefreshing sleep.

In the control group, the research team enrolled subjects without diagnosis of disease or injury.

Outcome Measures: The research team determined levels of serum reduced nicotinamide adenine dinucleotides (NADH and NAD[P]H) by measuring serum fluorescence emission at 450 nm. The team then conducted sensitivity and specificity analyses.

Results:
• NAD(P)H concentrations in serum of CFS participants averaged 8.0 +/- 1.4 (standard deviation [SD]) nmol/mL,

• While those in the healthy controls averaged 10.8 +/- 0.8 (SD) nmol/mL, a statistically significant difference.

Using a cut-off concentration of 9.5 nmol/mL, the research team attained a sensitivity of 0.73 and a specificity of 1.0. An analysis of receiver-operator characteristics yielded an area under the curve of 0.9.

The research team compared serum NAD(P)H to several endocrine and metabolic lab parameters. Serum NAD(P)H was directly correlated with serum CoQ10 levels and inversely correlated with urine hydroxyhemopyrrolin-2-one levels.

Conclusions: Based on these findings, the research team proposed using serum NAD(P)H, measured as an intrinsic serumfluorescence emission, to monitor metabolism and fatigue status in patients with CFS.

Following patients’ NAD(P)H levels over time may aid in selecting therapeutic strategies and monitoring treatment outcomes.

Source: Alternative Therapies, Jan-Feb 2012;18(1):36-40. ISSN#10786791 Mikirova N, Casciari J, Hunninghake R. Riordan Clinic, Wichita, Kansas, USA. [Email: nmikirova@riordanclinic.org]





Discuss This Article Post a Comment 


Objective test?
Posted by: KerryK
Apr 11, 2012
Wouldn't this qualify as an objective test?
Reply Reply
 
Free Chronic Fatigue Syndrome and Fibromyalgia Newsletters
Subscribe to
Our FREE
Newsletter
Subscribe Now!
Receive up-to-date ME/CFS & Fibromyalgia treatment and research news
 Privacy Guaranteed  |  View Archives

Featured Products

FibroSleep™ by ProHealth FibroSleep™ by ProHealth
The All-in-One Natural Sleep Aid
Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils
Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%
Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function
Optimized Curcumin Longvida® by ProHealth Optimized Curcumin Longvida® by ProHealth
Supports Cognition, Memory & Overall Health

Natural Remedies

Why Berries Offer a Rainbow of Health Benefits Why Berries Offer a Rainbow of Health Benefits
The Revolutionary 'Good Fat' That Promotes Heart, Brain, Bone and Joint Health The Revolutionary 'Good Fat' That Promotes Heart, Brain, Bone and Joint Health
2 test library cats 2 test library cats
Dreaming of a Good Night's Sleep? Dreaming of a Good Night's Sleep?
Protecting Our Eyes Against Time-Induced Damage Protecting Our Eyes Against Time-Induced Damage

FIBROMYALGIA RESOURCES
What is Fibromyalgia?
Fibromyalgia 101
Fibromyalgia Symptoms
Fibromyalgia Treatments
| CFS RESOURCES
What is CFS?
ME/CFS 101
ME/CFS Symptoms
ME/CFS Treatments
| FORUMS
Fibromyalgia
ME/CFS
ADVANCED MEDICAL LABS
WHOLESALE  |  AFFILIATES
GUARANTEE
CONTACT US
PRIVACY
RSS
SITE MAP
ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus
Credit Card Processing